Associations among serum concentrations of interleukin-18, matrix metalloproteinase-2 (MMP-2), tissue inhibitor of metalloproteinase-1 (TIMP-1) and METAVIR fibrosis score in patients with chronic hepatitis

References

• Friedman SL. Molecular mechanisms of hepatic fibrosis and principles of therapy. J Gastroenterol. 1997;32(3):424–430.
   PubMed Web of Science ®Google Scholar
• Arthur MJ. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiology Gastrointest Liver Physiol. 2000;279(2):G245–G249.
   PubMed Web of Science ®Google Scholar
• McCrudden R, Iredale JP. Liver fibrosis, the hepatic stellate cell and tissue inhibitors of metalloproteinases. Histol Histopathol. 2000;15(4):1159–1168.
   Web of Science ®Google Scholar
• Böker KH, Pehle B, Steinmetz C, Breitenstein K, Bahr M, Lichting-hagen R. Tissue inhibitors of metalloproteinases in liver and serum/ plasma in chronic active hepatitis C and HCV-induced cirrhosis. Hepatogastroenterology. 2000;47(33):812–819.
   Google Scholar
• Kasahara A, Hayashi N, Mochizuki K, et al. Circulating matrix met-alloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response. J Hepatol. 1997;26(3):574–583.
   Web of Science ®Google Scholar
• Mastroiani CM and Luzzi GM. Matrix metalloproteinase dysregulation in HIV infection: implications for therapeutic strategies. Trends Mol Med. 2007;13(11):449–459.
   Web of Science ®Google Scholar
• Connoy A, Turner J, Núñez M. Levels of serum markers of liver inflammation and fibrosis in patients with chronic hepatitis C virus infection according to HIV status and antiretroviral use. AIDS Res and Hum Retroviruses. 2011;27(7):719–725.
   Web of Science ®Google Scholar
• Fontana RJ, Goodman ZD, Dienstag JL, HALT-C Trial Group, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology. 2008;47(3):789–798.
   Web of Science ®Google Scholar
• Fontana RJ, Dienstag JL, Bonkovsky HL, HALT-C Trial Group, et al. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut. 2010;59(10):1401–1409.
   PubMed Web of Science ®Google Scholar
• Boeker KH, Haberkorn CI, Michels D, Fleming P, Manns MP, Lichtinghagen R. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta. 2002;316(1–2):71–81.
   Web of Science ®Google Scholar
• Lieber CS, Weiss DG, Paronetto F, Veterans Affairs Cooperative Study 391 Group. Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease. Alcohol Clin Exp Res. 2008;32(6):1031–1039.
   PubMed Web of Science ®Google Scholar
• Cheong JY, Um SH, Seo YK, et al. Non-invasive index for predicting significant liver fibrosis: comparison of diagnostic performances in patients with chronic hepatitis B and C. Dig Dis Sci. 2011;56(2):555–563.
   Web of Science ®Google Scholar
• Fabre V Wu H, Pond Tor S, et al. Tissue inhibitor of matrix metallopro-teinase-1 predicts risk of hepatic fibrosis in human Schistoma japonicum infection. J Infect Dis. 2011;203(5):707–714.
   Google Scholar
• Zhang Y, Li P, Li G, et al. The mechanism of how anti-IL-18 prevents concanavalin-A-induced hepatic fibrosis on a mouse model. J Surg Res. 2007;142(1):175–183.
   Web of Science ®Google Scholar
• Hanck C, Manigold T, Böcker U, et al. Gene expression of interleukin 18 in unstimulated peripheral blood mononuclear cells of patients with alcoholic cirrhosis. Gut. 2001;49(1):106–111.
   Web of Science ®Google Scholar
• Sharma A, Chakraborti A, Das A, Dhiman RK, Chawla Y Elevation of interleukin-18 in chronic hepatitis C: implications for hepatitis C virus pathogenesis. Immunology. 2009;128(Suppl 1):e514–e522.
   Web of Science ®Google Scholar
• Tapan S, Dogru T, Kara M, et al. Circulating levels of interleukin-18 in patients with non-alcoholic fatty liver disease. Scan J Clin Lab Invest. 2010;70(6):399–403.
   Web of Science ®Google Scholar
• Ludwiczek O, Kaser A, Novick D, et al. Plasma levels of interleukin-18 and interleukin-18 binding protein are elevated in patients with chronic liver disease. J Clin Immunol 2002;22(6):331–337.
   Web of Science ®Google Scholar
• Abdeen SM, Olusi SO, Askar HA, Thalib L, Al-Azemi A, George S. The predictive value of CD38 positive hepatic stellate cell count for assessing disease activity and fibrosis in patients with chronic hepatitis. ActaHistochem. 2009;111(6):520–530.
   Google Scholar
• Abdeen SM, Olusi SO. Peptidyl arginine deiminase: A novel immuno-histochemical marker for liver fibrosis in patients with chronic hepatitis. Acta Histochem. 2010;112(6):592–603.
   Web of Science ®Google Scholar
• Mihm S, Schweyer S, Ramadori G. Expression of the chemokine IP-10 correlates with the accumulation of hepatic IFN -gamma and IL-18 mRNA in chronic hepatitis C but not in hepatitis B. J Med Virol. 2003;70(4):562–570.
   Web of Science ®Google Scholar
• Schvoerer E, Navas MC, Thumann C, et al. Production of interleukin -18 and interleukin-12 in patients suffering from chronic hepatitis C virus infection before antiviral therapy. J Med Virol. 2003;70(4):588–593.
   Web of Science ®Google Scholar
• Xu GF, Li PT, Wang XY, et al. Dynamic changes in the expression of matrix metalloproteinases and their inhibitors, TIMPs, during hepatic fibrosis induced by alcohol in rats. World J Gastroenterol. 2004;10(24):3621–3627.
   Web of Science ®Google Scholar
• Dinarello CA. IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol. 1999;103(1 Pt 1):11–24.
   PubMed Web of Science ®Google Scholar
• Okamura H, Tsutsui H, Kashiwamura S, Yoshimoto T, Nakanishi K. Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 1998;70:281–312.
   PubMed Web of Science ®Google Scholar
• Murawaki Y, Yamada S, Ikuta Y, Kawasaki H. Clinical usefulness of serum matrix metalloproteinase-2, concentration in patients with chronic viral liver disease. J Hepatol. 1999;30(6):1090–1098.
   Web of Science ®Google Scholar
• Walsh KM, Timms P, Campbell S, MacSween RN, Morris AJ. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as non-invasive markers of liver disease in chronic hepatitis C; comparison using ROC analysis. Dig Dis Sci. 1999;44(3):624–630.
   Web of Science ®Google Scholar
• Kasahara A, Hayashi N, Mochizuki, O, et al. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response. J Hepatol. 1997;26(3):574–583.
   Web of Science ®Google Scholar
• Ebata M, Fukuda Y, Nakano I, Katano Y, Fujimoto N, Hayakawa T. Serum levels of tissue inhibitor of metalloproteinases-2 and of precursor form of matrix metalloproteinase-2 in patients with liver disease. Liver. 1997;17(6):293–299.
   Google Scholar
• Lichtinghagen R, Michels D, Haberkorn CI, et al. Matrix metalloproteinase (MMP)-2, MMP-7 and tissue inhibitor metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. J Hepatol. 2001;34(2):239–247.
   Web of Science ®Google Scholar